entertainment -WSS

entertainment

author：focus 2025-09-29 01:38:42 - browse：63

Apellis Pharmaceuticals said Tuesday that it had identified “internal structural variations” in a type of needle used by doctors to prepare syringes of its eye disease drug Syfovre as a possible cause of severe eye inflammation reported in patients receiving the treatment — but the company stopped short of definitively linking the needle to the cases.

Additionally, Apellis confirmed one additional case of the severe and potentially blinding side effect, known as retinal occlusive vasculitis, or ROV, that occurred in May. But with thousands of more Syfovre eye injections also performed, the overall frequency of ROV remains unchanged and rare, even with the added scrutiny and increased physician monitoring.

Apellis shares rose 30% to $40 in Wednesday’s pre-market trading on the growing belief amongst investors that Syfovre’s safety crisis is abating.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Readout LOUD podcast: Biotech layoffs, stock slump, 2024 preview

WSS

Duchenne drug from Nippon Shinyaku fails in rare confirmatory trial

Readout LOUD podcast: Biotech layoffs, stock slump, 2024 preview

Independent physicians launch a new lobbying group

Some medical students still think black patients feel less pain

Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

Biotech venture capitalists face new demands from investors

Wikipedia

entertainment

focus

Duchenne breakthrough therapy leaves behind pioneering families

Dewpoint Therapeutics lays off staff after losing partnerships

Duchenne breakthrough therapy leaves behind pioneering families

Protect nursing home residents from future pandemics

Alkermes shareholders re

eGenesis tests gene

At least 13 dead in Texas as scorching temps continue

Why doctors need education on FDA device approval process

Virginia high school admissions case could be legal follow

Parkinson’s finding may lead to tests and, someday, treatments

hotspot

Clinicians often fail to acknowledge the pain caused by long Covid

The HPV vaccine prevents cancer in men, too. Why do so few people get it?

Parkinson’s finding may lead to tests and, someday, treatments

eGenesis tests gene

Duchenne drug from Nippon Shinyaku fails in rare confirmatory trial

Beyond aggravation: Constipation is an American epidemic

focus

leisure time

hotspot

knowledge